Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Onartuzumab in combination with Vemurafenib and/or Cobimetinib in cancer patients has been withdrawn. The document notes the withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Cobimetinib (cobimetinib)
• Onartuzumab (onartuzumab)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: WITHDRAWN